Hoppn Shop by Color Search Technology is Available to Shopify Merchants Confluent and Alibaba Cloud Announce Partnership to set Data in Motion in Mainland China
SINGAPORE–(BUSINESS WIRE)–Confluent, Inc. (NASDAQ: CFLT), the platform for data in motion, and Alibaba Cloud, the…
RewirEd Summit – Driving Innovative, Radical Change in Global Education
Youth, skills & future of work focus on Day One B-Roll highlights available via: https://we.tl/t-6jJuSMLA2G…
EverGrow Coin Hyper Deflationary Token Is Setting New Standard in Defi
NEWARK, DE / ACCESSWIRE / December 12, 2021 / EverGrow Coin The Hyper Deflationary Token,…
Newly Launched Cryptocurrency EverGrow Coin Distributes $30M Passes 110K Token Holders and $30M in Rewards
NEWARK, DE / ACCESSWIRE / December 12, 2021 / Being the first cryptocurrency that rewards…
MorphoSys Presents Latest Data from the Phase 2 MANIFEST Study Evaluating the Potential of Pelabresib in the Treatment of Myelofibrosis
MorphoSys presents latest data from the Phase 2 MANIFEST Study evaluating the potential of pelabresib…
NFT Market Welcomes A New Rival: Socialogue – The Social NFT Marketplace
Vilnius, Lithuania–(Newsfile Corp. – December 12, 2021) – The NFT community celebrates the launch of…
New Concept Property Management has You Covered In Multiple Locations
TUCSON, AZ / ACCESSWIRE / December 12, 2021 / One of the biggest concerns landlords…
Blender Bites Announces Historic Record Revenues Over the Last Three Months: Representing a 2,266% Increase Compared to Same Period in 2020
VANCOUVER, BC / ACCESSWIRE / December 11, 2021 / Blender Bites Ltd. (the “Company“, “Blender…
Tessa Therapeutics Showcases Positive Clinical Data from Phase 1 Study of “Off the Shelf” CD30 Cell Therapy at 2021 Annual Meeting of American Society of Hematology (ASH)
Oral poster presentation highlights data from dose-escalation trial of allogeneic CD30.CAR EBVST cell therapy (TT11X)…
Neoleukin Therapeutics Announces Preclinical Data Highlighting Activity of NL-201 in Hematologic Malignancies at 63rd American Society of Hematology Annual Meeting (ASH 2021)
– Poster presentation highlights NL-201 activity in multiple myeloma stem cell transplant model – – Abstract…
Novartis Scemblix® demonstrates sustained response rate in 48-week follow-up in patients with chronic myeloid leukemia
Updated 48-week data from Phase III ASCEMBL trial consistent with improved major molecular response (MMR)…
Vincerx Pharma Presents Data on PTEFb/CDK9 Inhibitor VIP152 in DLBCL and CLL at the 63rd American Society of Hematology Annual Meeting
VIP152 has increased selectivity and potency compared to other CDK9 inhibitors in development, consistent across…
IGM Biosciences Presents Clinical Data from IGM-2323 in Patients with Advanced B Cell Malignancies at 2021 American Society of Hematology Annual Meeting
– Data Presented Shows Novel Bispecific IgM Antibody is Active in Heavily Pre-treated Patients with…
Novartis Kymriah® demonstrates strong responses in high-risk patients with relapsed or refractory follicular lymphoma in extended study follow-up
Complete and overall response rates and durability of response were well maintained across majority of…
Cellectis Reports Encouraging Clinical Data from BALLI-01 Study in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, and Preclinical Data from TALGlobin01 at the 63rd American Society of Hematology Annual Meeting
Cellectis’ Proprietary Product Candidate UCART22 was Administered after Lymphodepletion with Fludarabine, Cyclophosphamide and Alemtuzumab (FCA)…
Immunicum Presents Phase II Data Demonstrating Reduced MRD and Improved Survival with DCP-001 Treatment in AML Patients at ASH 2021
Press Release Stockholm, Sweden, December 11, 2021 Immunicum Presents Phase II Data Demonstrating Reduced MRD…
X4 Pharmaceuticals Presents New Clinical Data at ASH 2021 Further Supporting Potential of Mavorixafor + Ibrutinib to Treat Patients with Double-Mutation Waldenström’s Macroglobulinemia
Figure 1 Refractory Patients’ Serum IgM Levels After Treatment with Mavorixafor + Ibrutinib vs. Ibrutinib…
Harpoon Therapeutics Presents Interim Clinical Data from its Ongoing Phase 1/2 Study and New Preclinical Results for BCMA-targeting TriTAC® HPN217 at the 63rd ASH Annual Meeting and Exposition
Encouraging clinical activity in higher dose cohorts with 63% ORR and 88% DCR reported in…
Roche presents pivotal data at ASH 2021 for novel cancer immunotherapy mosunetuzumab
Results to be presented for the first time show mosunetuzumab induces high and durable complete…
Intel Breakthroughs Propel Moore’s Law Beyond 2025
Intel targets more than 10x density improvement in packaging and 30% to 50% logic scaling…